With the big product launch of Ezetimibe (a cholesterol-lowering drug), company's topline revenue to be over 25 percent, where 45 percent will be contributed by the US and 20-25 percent by the Indian business, says Glenn Saldanha, Chairman & MD of Glenmark Pharmaceuticals.
first published: May 13, 2016 10:23 am
A collection of the most-viewed Moneycontrol videos.
Live: RBI Policy Expectations| Rupee Slide, Strong GDP & Soft Inflation – Will MPC Cut Or Pause?
Nifty Holds Key Support; Volatile Trade Likely on Sensex Expiry | Opening Bell Live
Rupee Slide Weighs Heavy As Nifty Tests 25,900| Midcaps See Sharp Cuts| Closing Bell Live
Meesho's Rs 5,421 Cr IPO Kicks Off| Post-IPO Playbook, Profitability Path & More| IPO Watch Live
